Introduction
============

Esophageal cancer (EC) is the ninth most common cancer worldwide and the sixth leading cause of death due to cancer ([@b1-ol-0-0-11142],[@b2-ol-0-0-11142]). The main pathological subtypes include squamous cell carcinoma (SCC) and adenocarcinoma (AC) ([@b1-ol-0-0-11142]--[@b4-ol-0-0-11142]). In contrast to Western countries, where esophageal adenocarcinoma (EAC) is predominant, esophageal squamous cell carcinoma (ESCC) is predominant in some Asian countries, including Japan and China ([@b2-ol-0-0-11142]--[@b4-ol-0-0-11142]). EC remains a highly lethal malignant tumor, with poor prognosis, despite advances in diagnosis and treatment in recent decades. Approximately half of patients with EC have distant metastases at the time of initial diagnosis and more than one-third develop distant metastases following surgery or radiotherapy ([@b3-ol-0-0-11142],[@b5-ol-0-0-11142]). Although chemotherapy is standard treatment for patients with EC with distant organ metastases, the prognosis is dismal, with a five-year overall survival (OS) of less than 5% ([@b6-ol-0-0-11142],[@b7-ol-0-0-11142]). Most distant metastases of EC involve the distant lymph nodes, liver, and lungs ([@b8-ol-0-0-11142]--[@b10-ol-0-0-11142]).

Bone is a frequent site of metastasis from breast, prostate, and lung cancers ([@b11-ol-0-0-11142]--[@b13-ol-0-0-11142]), and bone metastasis (BM) typically indicates a poor prognosis. BM\'s incidence and prevalence has been increasing since a large portion of the population is elderly. Patients with BMs should be treated with a multidisciplinary approach, using modalities such as radiotherapy, surgery and various medical treatments that include chemotherapy, hormone therapy, and bone-modifying agents (BMAs) ([@b11-ol-0-0-11142]). BMs frequently cause skeletal-related events (SREs), such as pathological fracture, spinal cord compression, and hypercalcemia, which may require radiotherapy or surgery, and reduce physical function and quality of life ([@b14-ol-0-0-11142]). EC generally metastasizes to the skeletal system late in the course of the disease, so patients with EC with BMs are relatively uncommon. Several studies have reported BM incidence rates ranging from 5.2--7.7% in all-stage patients with EC and 15.3--23.6% in patients with metastases ([@b8-ol-0-0-11142]--[@b10-ol-0-0-11142],[@b15-ol-0-0-11142]). However, there is little information regarding the clinicopathological features and prognostic factors of patients with EC with BMs. Therefore, we aimed to investigate these features and factors retrospectively in patients with EC with BMs who were treated at our institution.

Materials and methods
=====================

### Study design and patients

We retrospectively and anonymously reviewed the medical records of 58 patients with EC, including five patients with esophagogastric junction (EGJ) cancers, who were diagnosed with BMs and treated at the Osaka International Cancer Institute between January 2007 and December 2016. The inclusion criteria were: 1) histological diagnosis of SCC or AC with the esophagus or EGJ recognized as the primary tumor; 2) BM diagnosis based on clinical signs and symptoms as well as radiographic imaging studies, such as computed tomography (CT), magnetic resonance imaging (MRI), and fluorodeoxyglucose-positron emission tomography (FDG-PET)/CT. The exclusion criteria was: 1) patients with other synchronous malignancies. The Institutional Review Board of the Osaka International Cancer Institute approved the study.

### Data collection

Patient data, including age, sex, and Eastern Cooperative Oncology Group performance status (ECOG PS), was collected. Tumor characteristics, including location, histology, differentiation, resection of primary site, visceral or brain metastasis, and serum levels of SCC antigen (SCC-Ag), carcinoembryonic antigen (CEA), C-reactive protein (CRP), lactate dehydrogenase (LDH), albumin, and alkaline phosphatase (ALP), were also noted. BM characteristics, including presence at initial diagnosis, number, type (osteolytic, osteoblastic, mixed, and intertrabecular), SRE, pathological fracture, spinal cord compression, hypercalcemia, and treatment received (chemotherapy before and after the BM diagnosis, BMA, radiotherapy, and surgery), as well as follow-up period and outcome at last follow-up were determined.

### Statistical analysis

OS, defined as the time from the date of BM diagnosis to the date of death from any cause or last follow-up visit, was calculated using the Kaplan-Meier method. The impact of prognostic factors on OS was first assessed using the log-rank test in univariate analysis, and then multivariate analysis was performed using the Cox proportional hazard model with variables chosen using a forward conditional stepwise approach. Statistical significance was defined as *P*\<0.05. Statistical analyses were performed using EZR software (Saitama Medical Center, Jichi Medical University, Saitama, Japan), a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria).

Results
=======

### Patient and tumor-related characteristics

Fifty-eight patients diagnosed with BMs from EC were enrolled in this study. The median follow-up period for all patients was three months (range, 0--54). Patient and tumor characteristics are shown in [Table I](#tI-ol-0-0-11142){ref-type="table"}. Fifty-three patients (91.4%) were male and five (8.6%) were female. The median age was 67 years (range, 39--84). ECOG PS was 0--2 in 35 patients (60.3%) and 3--4 in 23 patients (39.7%). Tumor location was esophagus in 53 patients (91.4%) and EGJ in five patients (8.6%). Tumor histology of the primary lesion was SCC in 54 patients (93.1%) and AC in four patients (6.9%). Among the 32 patients whose tumor differentiation was evaluated, 12 (37.5%) had poorly differentiated tumors and 20 (62.5%) had well to moderately differentiated tumors. Twenty-four patients (41.4%) underwent surgery for their primary tumor. Visceral or brain metastasis was observed at the time of BM diagnosis in 38 patients (65.5%). Elevated levels of serum SCC-Ag (\>1.5 ng/ml), CEA (\>5 ng/ml), CRP (\>0.3 mg/dl), LDH (\>250 U/l), and ALP (\>350 U/l) at the time of BM diagnosis were observed in 68.8, 27.5, 75.4, 27.8, and 30.9% of patients, respectively. Decreased serum albumin level (≤3.7 g/dl) was detected in 65.5% of the patients.

### Bone metastasis-related characteristics

The median interval from the diagnosis of EC to BM detection was seven months (range, 0--80). BM characteristics are shown in [Table II](#tII-ol-0-0-11142){ref-type="table"}. Fourteen patients (24.1%) had BMs at initial presentation. A solitary BM was found in 20 patients (34.5%) and multiple BMs were detected in 38 patients (65.5%). Frequent metastatic sites included the thoracic vertebrae (31 patients, 53.4%), lumbar vertebrae (18 patients, 31.0%) and pelvic bones (16 patients, 27.6%). The bone metastatic lesions were osteolytic in 52 patients (89.7%), mixed in two (3.4%), and intertrabecular in four (6.9%). No patient showed an osteoblastic type of BM. Chemotherapy was administered before the diagnosis of BM in 38 patients (65.5%), and 32 patients (55.2%) received palliative chemotherapy after the BM diagnosis. BMAs, such as zoledronic acid and denosumab, were administered to 19 patients (32.8%).

### Skeletal-related events

SREs occurred in 53 patients (91.4%), including radiation therapy (48 patients, 82.8%), surgery (four patients, 6.9%), pathological fracture (13 patients, 22.4%), spinal cord compression (six patients, 10.3%), and hypercalcemia (15 patients, 30.0%). SREs occurred at the time of the BM diagnosis in 44 patients. In the remaining nine patients, the median time from identification of BM to SRE was two months (range, 1--13). The association between type of BMs and interval from BM diagnosis to SREs was shown in [Table III](#tIII-ol-0-0-11142){ref-type="table"}.

### Predictive factors of OS

The six-month, one-year, and two-year OS rates after BM diagnosis were 48.7, 25.3, and 6.1%, respectively ([Fig. 1](#f1-ol-0-0-11142){ref-type="fig"}). The median OS following BM diagnosis was five months (range, 0--54). In univariate analyzes, ECOG PS (P\<0.001), visceral or brain metastasis (*P*=0.018), serum levels of CEA (*P*=0.012), CRP (*P*=0.011), albumin (*P*=0.018), and receipt of chemotherapy following BM diagnosis (*P*\<0.001) were significant prognostic factors ([Tables I](#tI-ol-0-0-11142){ref-type="table"}, [II](#tII-ol-0-0-11142){ref-type="table"}, [Fig. 2A-F](#f2-ol-0-0-11142){ref-type="fig"}). The prognosis of EGJ cancer was not significantly different from other types of EC (*P*=0.373). Tumor histology was also not a significant impact on OS (*P*=0.272). Multivariate analyzes showed that elevated serum CEA level (hazard ratio (HR) 2.400; 95% confidence interval (CI) 1.020--5.649; *P*=0.045) and no chemotherapy following the diagnosis of BM (HR 2.621; 95% CI 1.015--6.769; *P*=0.046) were significant independent prognostic factors for poor OS ([Table IV](#tIV-ol-0-0-11142){ref-type="table"}).

Smokers tend to have higher CEA levels and the majority of patients with EC must have been heavy smokers (data not shown). However, the cutoff line of 5.0 ng/ml was chosen in accordance with previous studies ([@b16-ol-0-0-11142],[@b17-ol-0-0-11142]). There were 10 patients who had SCC histologically but elevated serum CEA levels ranging from 5.2 to 55 ng/ml. The prognosis of those patients was also significantly worse than that of the patients with SCC who had no elevation of CEA level (26 patients, P=0.014).

Among 35 patients with EC with BMs whose ECOG PS was 0--2 at BM diagnosis, 26 patients (74.3%) received chemotherapy after BM diagnosis. On the other hand, among 23 patients with ECOG PS of 3--4, only six patients (26.1%) received chemotherapy after BM diagnosis. The patients with ECOG PS of 0--2 who underwent chemotherapy after BM diagnosis tended to show better prognosis than those who did not. However, there was no statistically significant difference between the two groups (*P*=0.183).

Discussion
==========

BMs are generally categorized, based on morphology, as osteolytic, osteoblastic, mixed, or intertrabecular. In osteolytic lesions, factors secreted by tumor cells induce osteoclast recruitment and activation, leading to increased osteolysis ([@b12-ol-0-0-11142]). This frequently decreases bone integrity and causes severe bone pain, an increased risk of fracture, and the release of minerals from the bone matrix, which results in hypercalcemia ([@b14-ol-0-0-11142]). For these reasons, osteolytic BMs are associated with a higher probability of SREs, which frequently cause morbidity and deterioration of PS. In turn, poor PS may prevent a patient from receiving further available treatment. Metastases from lung, kidney, and thyroid cancers are predominantly osteolytic. In this study of patients with EC with BMs, multiple osteolytic BMs commonly occurred in the axial skeleton, and SREs occurred in nearly all (91.4%) patients. Therefore, physicians caring for patients with EC should consider BM in the differential diagnosis when a patient complains of spontaneous somatic axial pain. Additionally, when routine follow-up CT reveals osteolytic changes in a vertebral body, BM should be suspected. Serum ALP, LDH, and tumor markers, including SCC-Ag and CEA, are not always elevated when BMs are present. Since MRI and FDG-PET/CT are able to easily detect BMs from EC ([@b18-ol-0-0-11142],[@b19-ol-0-0-11142]), using these modalities can allow early and accurate diagnosis to prevent SREs and preserve PS.

Currently, palliative radiotherapy for painful BM is a well-established treatment. However, some patients with fracture, spinal cord compression, or spinal instability due to BM require surgery, if their life expectancy is not too short. Conversely, patients with a short life expectancy should receive radiotherapy and/or supportive care. Therefore, accurate survival data regarding patients with BMs is necessary so appropriate treatment recommendations can be made. In breast cancer, patients with BMs have significantly better survival than those who have metastases to other sites ([@b20-ol-0-0-11142]). On the other hand, OS is significantly worse in patients with EC with BMs compared to those with metastases to other sites ([@b9-ol-0-0-11142],[@b21-ol-0-0-11142]). In the current study, the median OS from the time of BM diagnosis in patients with EC was five months, which is consistent with previous reports of 2--4 months ([@b9-ol-0-0-11142],[@b22-ol-0-0-11142]). These results suggest that the prognosis of patients with EC with BMs is usually poor and that palliative radiotherapy is a standard treatment for those patients. However, for example, surgical treatment is widely considered more effective for pathologic proximal femur fractures than radiotherapy because they are mainly treated with surgery to stabilize the fractured bones to improve quality of life via pain relief and restoration of function and mobility. Operative methods are divided into internal fixation and prosthesis replacement. Only palliative surgery such as internal fixation may be appropriate for patients with EC with BMs. On the other hand, despite relatively common perioperative complications, salvage using endoprostheses is associated with fewer failures for the treatment of pathologic proximal fractures compared with internal fixation ([@b23-ol-0-0-11142]--[@b25-ol-0-0-11142]). Araki *et al* ([@b26-ol-0-0-11142]) reported that with regard to bone destruction, the involvement of the head, neck, calcar, and intertrochanteric region, transverse destruction \>1/2, and soft-tissue tumor extension, were the factors that led to the choice of prosthesis treatment.

Katagiri *et al* ([@b22-ol-0-0-11142]) identified six significant prognostic factors for survival in patients with BMs: the primary lesion, visceral or cerebral metastases, abnormal laboratory data, poor PS, previous chemotherapy and multiple skeletal metastases. The study included patients with BMs from various cancers. Wu *et al* ([@b9-ol-0-0-11142]) demonstrated the relationship between the patterns of distant metastasis and prognosis in metastatic EC. The most common site of distant metastasis was the liver, followed by distant lymph nodes, lungs, bone and brain. Site and number of distant metastases were independent prognostic factors for OS. OS was worst for BMs and greatest for distant lymph node metastases. However, clinicopathological features and prognostic factors of patients with EC with BMs remain unknown. To the best of our knowledge, the present study is the first to report clinicopathological features and prognostic factors in patients with EC with BMs. Although univariate analysis showed that visceral or brain metastasis, abnormal serum CRP and albumin levels, and PS were significant prognostic factors, multivariate analysis found that these factors were not significantly associated with OS. Only elevated serum CEA level and no chemotherapy following BM diagnosis were shown to be significant independent poor prognostic factors.

Serum tumor markers play an important role in cancer diagnosis and prognosis. CEA is relevant in several malignancies, such as colorectal, lung, and breast cancers. In general, CEA is a useful marker for EAC; however, it has been reported that CEA was positive in only 11.4 to 39% of patients with ESCC ([@b27-ol-0-0-11142],[@b28-ol-0-0-11142]). In the present study, tumor histology was SCC in most patients (93.1%), and SCC-Ag showed a higher positivity rate (68.8%) than CEA (27.5%) at the time of BM diagnosis. Some studies have noted that SCC-Ag was a better OS predictor in patients with EC ([@b29-ol-0-0-11142]--[@b31-ol-0-0-11142]), while other studies have demonstrated CEA\'s efficacy as a diagnostic and prognostic marker in patients with EC ([@b17-ol-0-0-11142],[@b32-ol-0-0-11142],[@b33-ol-0-0-11142]). Until now, there has been no agreement on which biomarker is the best predictor for prognosis in patients with EC with BMs. In the current study, tumor histology was not associated with patients with OS with EC. Multivariate analysis showed that serum CEA level was an independent prognostic factor, but serum SCC-Ag level was not. CEA is associated with adhesion of malignant tumors, which might explain the correlation between CEA level and hematogenic metastasis such as BM.

Chemotherapy improves survival compared to supportive care alone in patients with metastatic EC, but the improvement is modest and must be weighed against the side effects of chemotherapy ([@b34-ol-0-0-11142]). First-line chemotherapy usually includes platinum-based agents, such as cisplatin and oxaliplatin, and a fluoropyrimidine, such as fluorouracil and capecitabine ([@b34-ol-0-0-11142]--[@b36-ol-0-0-11142]). The addition of a third drug, such as epirubicin or docetaxel, might be considered for patients who are generally in good health ([@b35-ol-0-0-11142],[@b36-ol-0-0-11142]). Second-line chemotherapy with docetaxel, paclitaxel, or irinotecan might be considered for patients with stable PS ([@b37-ol-0-0-11142]--[@b39-ol-0-0-11142]). In the present study, the patients with good PS who received chemotherapy after BM diagnosis tended to show better prognosis than those who did not, but there was no significant difference between the two groups. One reason may be that a patient with good PS who did not undergo chemotherapy after BM diagnosis had been alive for 54 months. This patient had a solitary rib BM and no visceral or brain metastasis. The BM was treated with radiotherapy and no other metastatic lesion had occurred. ECOG PS and chemotherapy after BM diagnosis ware significant prognostic factors for OS in univariate analyses. However, only receipt of chemotherapy but not good PS was associated with better OS in multivariate analyses. The prognosis of patients with EC with BMs who did not receive chemotherapy due to poor PS, advanced age, comorbidity, or patient refusal was dismal. Our results indicate that chemotherapy should be considered, whenever possible, at the time of BM diagnosis in patients with EC.

In conclusion, the prognosis of BM from EC was extremely poor, with a median OS of five months following BM diagnosis. Multiple osteolytic BMs occurred predominantly in the axial skeleton with a high incidence of SREs. Univariate analysis showed that PS, visceral or brain metastasis, receipt of chemotherapy following the diagnosis of BM, and serum CEA, CRP, and albumin levels were significant prognostic factors for OS. Multivariate analysis demonstrated that no chemotherapy following the diagnosis of BM and elevated CEA level were independent prognostic factors for poor OS. In patients with EC with BMs, early diagnosis and appropriate treatment could prevent SREs and maintain quality of life and PS, allowing continuation of chemotherapy.
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![Kaplan-Meier survival curve for OS in all 58 patients with EC with bone metastases. OS, overall survival; EC, esophageal cancer.](ol-19-01-0717-g00){#f1-ol-0-0-11142}
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###### 

Patient and tumor-related characteristics and univariate analysis of prognostic factors for OS.

  Factors                        Number (%)   1-year OS, %   P-value
  ------------------------------ ------------ -------------- ---------
  Age, years                                                 0.701
    \<65                         22 (37.9)    21.9           
    ≥65                          36 (62.1)    28.3           
  Sex                                                        0.719
    Male                         53 (91.4)    25.2           
    Female                       5 (8.6)      25.0           
  ECOG PS                                                    \<0.001
    0--2                         35 (60.3)    34.7           
    3--4                         23 (39.7)    7.6            
  Location                                                   0.373
    Esophagus                    53 (91.4)    28.6           
    EGJ                          5 (8.6)      0              
  Histology                                                  0.272
    SCC                          54 (93.1)    27.9           
    AC                           4 (6.9)      0              
  Differentiation                                            0.536
    Poorly                       12 (37.5)    41.9           
    Moderately/Well              20 (62.5)    23.8           
  Resection of primary site                                  0.224
    Yes                          24 (41.4)    37.3           
    No                           34 (58.6)    16.1           
  Visceral or brain metastasis                               0.018
    Present                      38 (65.5)    17.2           
    Absent                       20 (34.5)    41.9           
  SCC, ng/ml                                                 0.389
    ≤1.5                         15 (31.3)    39.6           
    \>1.5                        33 (68.8)    25.5           
  CEA, ng/ml                                                 0.012
    ≤5                           29 (72.5)    37.2           
    \>5                          11 (27.5)    18.2           
  CRP, mg/dl                                                 0.011
    ≤0.3                         14 (24.6)    42.3           
    \>0.3                        43 (75.4)    20.5           
  LDH, U/l                                                   0.213
    ≤250                         39 (72.2)    28.5           
    \>250                        15 (27.8)    9.3            
  Albumin, g/dl                                              0.018
    ≤3.7                         36 (65.5)    15.2           
    \>3.7                        19 (34.5)    43.8           
  ALP, U/l                                                   0.878
    ≤350                         38 (69.1)    24.7           
    \>350                        17 (30.9)    25.9           

OS, overall survival; ECOG PS, Eastern Cooperative Oncology Group performance status; EGJ, esophagogastric junction; SCC, squamous cell carcinoma; AC, adenocarcinoma; CEA, carcinoembryonic antigen; CRP, C-reactive protein; LDH, lactate dehydrogenase; ALP, alkaline phosphatase.

###### 

BM-related characteristics and univariate analysis of prognostic factors for OS.

  Factors                     Number (%)   1-year OS, %   P-value
  --------------------------- ------------ -------------- ---------
  BM at initial diagnosis                                 
    Yes                       14 (24.1)    30.8           0.270
    No                        44 (75.9)    23.5           
  Number of BM                                            
    Solitary                  20 (34.5)    21.6           0.932
    Multiple                  38 (65.5)    27.2           
  Type of BM                                              
    Osteolytic                52 (89.7)    25.5           0.745
    Mixed/intertrabecular     6 (10.3)     22.2           
  Chemotherapy before BM                                  
    Yes                       38 (65.5)    22.0           0.240
    No                        20 (34.5)    30.6           
  Chemotherapy after BM                                   
    Yes                       32 (55.2)    37.7           \<0.001
    No                        26 (44.8)    6.5            
  Use of BMA                                              
    Yes                       19 (32.8)    38.3           0.147
    No                        39 (67.2)    18.8           
  SRE                                                     
    Present                   53 (91.4)    25.1           0.836
    Absent                    5 (8.6)      30 (6-month)   
  Radiotherapy for BM                                     
    Yes                       48 (82.8)    23.6           0.978
    No                        10 (17.2)    40.0           
  Orthopedic surgery for BM                               
    Yes                       4 (6.9)      25.0           0.956
    No                        54 (93.1)    25.7           
  Pathological fracture                                   
    Present                   13 (22.4)    30.8           0.559
    Absent                    45 (77.6)    22.5           
  Spinal cord compression                                 
    Present                   6 (10.3)     31.2           0.429
    Absent                    52 (89.7)    24.8           
  Hypercalcemia                                           
    Present                   15 (30.0)    10.0           0.086
    Absent                    35 (70.0)    28.9           

Since the one-year OS in patients in whom SRE did not occur could not be calculated, the 6-month OS is shown. BM, bone metastasis; OS, overall survival; BMA, bone-modifying agent; SRE, skeletal-related event.

###### 

Association between type of BMs and interval from BM diagnosis to SREs.

                                   Timing of SRE occurrence                 
  ----------------- -------------- -------------------------- ------------- ------------------
  Osteolytic        49/52 (94.2)   41/49 (83.7)               8/49 (16.3)   4 (range, 1--13)
  Mixed             1/2 (50)       1/1 (100)                  0/1 (0)       --
  Intertrabecular   3/4 (75)       2/3 (66.7)                 1/3 (33.3)    1
  Total             53/58 (91.4)   44/53 (83)                 9/53 (17)     2 (range, 1--13)

BM, bone metastasis; SRE, skeletal-related event.

###### 

Multivariate analysis of prognostic factors for OS.

                                 Univariate analysis   Multivariate analysis                  
  ------------------------------ --------------------- ----------------------- -------------- -------
  ECOG PS                                                                                     
    0--2                         \<0.001               1                                      
    3--4                                               2.034                   0.698--5.922   0.193
  Visceral or brain metastasis                                                                
    Present                      0.018                 1.444                   0.529--3.938   0.473
    Absent                                             1                                      
  CEA, ng/ml                                                                                  
    ≤5                           0.012                 1                                      
    \>5                                                2.400                   1.020--5.649   0.045
  CRP, mg/dl                                                                                  
    ≤0.3                         0.011                 1                                      
    \>0.3                                              2.230                   0.692--7.183   0.179
  Albumin, g/dl                                                                               
    ≤3.7                         0.018                 1.052                   0.386--2.868   0.921
    \>3.7                                              1                                      
  Chemotherapy after BM                                                                       
    Yes                          \<0.001               1                                      
    No                                                 2.621                   1.015--6.769   0.046

OS, overall survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; CEA, carcinoembryonic antigen; CRP, C-reactive protein.
